2.1 Surrogate endpoint validation and regulatory acceptance

Apply surrogate validation frameworks—including the Prentice criteria, meta-analytic methods, and the FDA three-tier evidentiary hierarchy—to evaluate whether a candidate surrogate endpoint is fit for regulatory use, and analyze the strategic trade-offs of accelerated approval on a surrogate versus traditional approval on a clinical endpoint.

2.2 Composite endpoint design and interpretation

Design composite endpoints that improve statistical efficiency without sacrificing clinical interpretability—component selection criteria, hierarchical analysis methods (win ratio, Finkelstein-Schoenfeld), regulatory guidance on component acceptability, and the sensitivity analysis plan that addresses heterogeneity concerns.

2.3 Patient-reported outcomes in protocol design

Integrate patient-reported outcomes into protocol design with measurement science rigor—from instrument evaluation using FDA PRO Guidance and COSMIN standards, through responder definition and missing data prevention, to building the evidentiary case for PRO-based labeling claims.

2.4 Digital, imaging, and novel endpoint modalities

Evaluate the regulatory readiness of digital health technology-derived endpoints, design imaging endpoint assessment plans with central reading rigor, and apply FDA and EMA frameworks for novel endpoint acceptance to plan a regulatory engagement strategy around non-traditional primary endpoints.

3.1 Designing inclusion and exclusion criteria

Design inclusion and exclusion criteria that serve the scientific question without introducing unnecessary restrictions, evaluate each criterion against the standard of necessity, and apply FDA guidance on broadening eligibility to create trial populations that are both scientifically rigorous and operationally feasible.

3.2 Enrichment strategies in clinical trial design

Apply the FDA Enrichment Strategies framework to select prognostic, predictive, or practical enrichment approaches for a clinical program, evaluate the trade-offs between enrichment-driven trial efficiency and constraints on label scope, and design biomarker-driven enrichment strategies that align with companion diagnostic co-development and pivotal trial timelines.

3.3 Diversity, equity, and generalizability in trial populations

Design a diversity action plan meeting FDORA Section 3601 requirements, apply the PRECIS-2 framework to position a trial on the explanatory-pragmatic spectrum, evaluate how protocol design decisions systematically affect population diversity, and assess how trial population composition determines label scope and real-world applicability.

4.1 Sample size, power, and effect size estimation

Evaluate the key inputs to sample size calculations as strategic protocol parameters, challenge effect size assumptions through data triangulation, design sample size strategies for event-driven trials, and assess when mid-trial sample size re-estimation is appropriate under adaptive design frameworks.

4.2 The estimands framework (ICH E9(R1))

Define estimand attributes, select intercurrent event strategies aligned with the clinical question, evaluate how estimand choices shape protocol design, and construct sensitivity analysis frameworks that address key assumptions.

4.3 Multiplicity, interim analysis, and alpha management

Design endpoint testing hierarchies that protect the primary endpoint, evaluate alpha-spending approaches for interim analyses, distinguish stopping rules for efficacy, futility, and safety, and communicate multiplicity strategy rationale to non-statistical stakeholders.

4.4 Missing data prevention and analysis strategies

Design protocol-level strategies to minimize missing data, evaluate the assumptions underlying MCAR, MAR, and MNAR mechanisms, align missing data handling with the trial's primary estimand, and construct sensitivity analysis plans that satisfy regulatory expectations.

5.1 Adaptive design mechanics and regulatory framework

Classify adaptive design elements by type, evaluate the FDA and EMA regulatory frameworks governing their use, assess the operational infrastructure required for execution, and apply the complexity calculus to determine when adaptations genuinely improve a trial versus when they introduce unacceptable burden.

5.2 Seamless and dose-finding designs

Distinguish between operationally and inferentially seamless Phase II/III designs, evaluate adaptive dose-finding methods across trial phases, design the statistical framework for combining learning and confirming within a single trial, and assess how FDA Project Optimus reshapes dose optimization strategy.

5.3 Master protocols: basket, umbrella, and platform trials

Distinguish between basket, umbrella, and platform trial frameworks, evaluate the statistical methods and governance structures each requires, and apply lessons from landmark master protocols to feasibility assessment for proposed multi-arm programs.

5.4 Bayesian approaches in clinical trial design

Evaluate Bayesian methods for clinical trial design—including prior specification, posterior probability-based decision rules, adaptive randomization, and dynamic borrowing of external data—and assess their regulatory acceptability relative to frequentist alternatives.

6.1 Protocol complexity and amendment prevention

Analyze the evidence on protocol complexity escalation and amendment epidemiology, apply root cause analysis to identify preventable amendment drivers, and design feasibility-grounded optimization strategies that eliminate unnecessary protocol burden without sacrificing scientific rigor.

6.2 Site and patient burden optimization

Design visit schedules that balance scientific needs with participant tolerance, rationalize protocol-driven assessments against standard of care, embed retention strategies directly into the protocol, and optimize informed consent for both comprehensiveness and comprehensibility.

6.3 Decentralized trials and digital health technologies

Evaluate which decentralized trial elements are appropriate for a given protocol, design eConsent processes that meet 21 CFR Part 11 and ICH E6(R3) requirements, assess data integrity risks unique to remote trial conduct, and architect hybrid trial models that optimize participant access without compromising regulatory-grade data quality.

7.1 Real-world evidence and external controls in trial design

Evaluate real-world data sources for fitness-for-purpose in augmenting clinical trials, assess when external control arms are scientifically and regulatorily appropriate, design hybrid evidence strategies combining randomized and real-world evidence components, and apply lessons from regulatory precedent to assess the feasibility of an RWE strategy.

7.2 Benefit-risk assessment in protocol design decisions

Apply structured benefit-risk frameworks as protocol design tools to justify comparator selection, placebo use, dose decisions, and population restrictions, while embedding proportionate risk mitigation and communicating the rationale to regulators, IRBs, and investigators.

7.3 Regulatory alignment of protocol design

Design protocols that incorporate prior regulatory feedback, harmonize FDA and EMA expectations within a single global trial, leverage Special Protocol Assessment strategically, and anticipate reviewer questions before they are asked.

7.4 Protocol design synthesis: putting it all together

Synthesize endpoint, population, statistical, adaptive, and operational design decisions into a coherent protocol strategy, navigate cross-domain trade-offs using a structured decision framework, and evaluate completed protocols against a comprehensive quality checklist.

2.1 Surrogate endpoint validation and regulatory acceptance

Apply surrogate validation frameworks—including the Prentice criteria, meta-analytic methods, and the FDA three-tier evidentiary hierarchy—to evaluate whether a candidate surrogate endpoint is fit for regulatory use, and analyze the strategic trade-offs of accelerated approval on a surrogate versus traditional approval on a clinical endpoint.

2.2 Composite endpoint design and interpretation

Design composite endpoints that improve statistical efficiency without sacrificing clinical interpretability—component selection criteria, hierarchical analysis methods (win ratio, Finkelstein-Schoenfeld), regulatory guidance on component acceptability, and the sensitivity analysis plan that addresses heterogeneity concerns.

2.3 Patient-reported outcomes in protocol design

Integrate patient-reported outcomes into protocol design with measurement science rigor—from instrument evaluation using FDA PRO Guidance and COSMIN standards, through responder definition and missing data prevention, to building the evidentiary case for PRO-based labeling claims.

2.4 Digital, imaging, and novel endpoint modalities

Evaluate the regulatory readiness of digital health technology-derived endpoints, design imaging endpoint assessment plans with central reading rigor, and apply FDA and EMA frameworks for novel endpoint acceptance to plan a regulatory engagement strategy around non-traditional primary endpoints.

3.1 Designing inclusion and exclusion criteria

Design inclusion and exclusion criteria that serve the scientific question without introducing unnecessary restrictions, evaluate each criterion against the standard of necessity, and apply FDA guidance on broadening eligibility to create trial populations that are both scientifically rigorous and operationally feasible.

3.2 Enrichment strategies in clinical trial design

Apply the FDA Enrichment Strategies framework to select prognostic, predictive, or practical enrichment approaches for a clinical program, evaluate the trade-offs between enrichment-driven trial efficiency and constraints on label scope, and design biomarker-driven enrichment strategies that align with companion diagnostic co-development and pivotal trial timelines.

3.3 Diversity, equity, and generalizability in trial populations

Design a diversity action plan meeting FDORA Section 3601 requirements, apply the PRECIS-2 framework to position a trial on the explanatory-pragmatic spectrum, evaluate how protocol design decisions systematically affect population diversity, and assess how trial population composition determines label scope and real-world applicability.

4.1 Sample size, power, and effect size estimation

Evaluate the key inputs to sample size calculations as strategic protocol parameters, challenge effect size assumptions through data triangulation, design sample size strategies for event-driven trials, and assess when mid-trial sample size re-estimation is appropriate under adaptive design frameworks.

4.2 The estimands framework (ICH E9(R1))

Define estimand attributes, select intercurrent event strategies aligned with the clinical question, evaluate how estimand choices shape protocol design, and construct sensitivity analysis frameworks that address key assumptions.

4.3 Multiplicity, interim analysis, and alpha management

Design endpoint testing hierarchies that protect the primary endpoint, evaluate alpha-spending approaches for interim analyses, distinguish stopping rules for efficacy, futility, and safety, and communicate multiplicity strategy rationale to non-statistical stakeholders.

4.4 Missing data prevention and analysis strategies

Design protocol-level strategies to minimize missing data, evaluate the assumptions underlying MCAR, MAR, and MNAR mechanisms, align missing data handling with the trial's primary estimand, and construct sensitivity analysis plans that satisfy regulatory expectations.

5.1 Adaptive design mechanics and regulatory framework

Classify adaptive design elements by type, evaluate the FDA and EMA regulatory frameworks governing their use, assess the operational infrastructure required for execution, and apply the complexity calculus to determine when adaptations genuinely improve a trial versus when they introduce unacceptable burden.

5.2 Seamless and dose-finding designs

Distinguish between operationally and inferentially seamless Phase II/III designs, evaluate adaptive dose-finding methods across trial phases, design the statistical framework for combining learning and confirming within a single trial, and assess how FDA Project Optimus reshapes dose optimization strategy.

5.3 Master protocols: basket, umbrella, and platform trials

Distinguish between basket, umbrella, and platform trial frameworks, evaluate the statistical methods and governance structures each requires, and apply lessons from landmark master protocols to feasibility assessment for proposed multi-arm programs.

5.4 Bayesian approaches in clinical trial design

Evaluate Bayesian methods for clinical trial design—including prior specification, posterior probability-based decision rules, adaptive randomization, and dynamic borrowing of external data—and assess their regulatory acceptability relative to frequentist alternatives.

6.1 Protocol complexity and amendment prevention

Analyze the evidence on protocol complexity escalation and amendment epidemiology, apply root cause analysis to identify preventable amendment drivers, and design feasibility-grounded optimization strategies that eliminate unnecessary protocol burden without sacrificing scientific rigor.

6.2 Site and patient burden optimization

Design visit schedules that balance scientific needs with participant tolerance, rationalize protocol-driven assessments against standard of care, embed retention strategies directly into the protocol, and optimize informed consent for both comprehensiveness and comprehensibility.

6.3 Decentralized trials and digital health technologies

Evaluate which decentralized trial elements are appropriate for a given protocol, design eConsent processes that meet 21 CFR Part 11 and ICH E6(R3) requirements, assess data integrity risks unique to remote trial conduct, and architect hybrid trial models that optimize participant access without compromising regulatory-grade data quality.

7.1 Real-world evidence and external controls in trial design

Evaluate real-world data sources for fitness-for-purpose in augmenting clinical trials, assess when external control arms are scientifically and regulatorily appropriate, design hybrid evidence strategies combining randomized and real-world evidence components, and apply lessons from regulatory precedent to assess the feasibility of an RWE strategy.

7.2 Benefit-risk assessment in protocol design decisions

Apply structured benefit-risk frameworks as protocol design tools to justify comparator selection, placebo use, dose decisions, and population restrictions, while embedding proportionate risk mitigation and communicating the rationale to regulators, IRBs, and investigators.

7.3 Regulatory alignment of protocol design

Design protocols that incorporate prior regulatory feedback, harmonize FDA and EMA expectations within a single global trial, leverage Special Protocol Assessment strategically, and anticipate reviewer questions before they are asked.

7.4 Protocol design synthesis: putting it all together

Synthesize endpoint, population, statistical, adaptive, and operational design decisions into a coherent protocol strategy, navigate cross-domain trade-offs using a structured decision framework, and evaluate completed protocols against a comprehensive quality checklist.